Infertility is one of the most common non-communicable diseases,affecting both men and women equally.Ovarian reserve,the number of primordial follicles in the ovaries is believed to be the most important determinants ...Infertility is one of the most common non-communicable diseases,affecting both men and women equally.Ovarian reserve,the number of primordial follicles in the ovaries is believed to be the most important determinants for female fertility.Anti-Mullerian hormone(AMH)secreted from granulosa cells of growing follicles is recognized as the most important biomarker for ovarian reserve.Ovarian reserve models have been developed using AMH and other hormonal indicators,thus childbearing plans and reproductive choices could be arranged by women.In assisted reproductive technology cycles,measurement of AMH helps to predict ovarian response and guide recombinant follicle-stimulating hormone dosing in women.Serum AMH level is increasingly being recognized as a potential surrogate marker for polycystic ovarian morphology,one of the criteria for diagnosis of polycystic ovarian syndrome.AMH is also secreted by Sertoli cells of testes in men,and AMH measurements in the prediction of surgical sperm recovery rate in men have also been investigated.AMH levels are significantly higher in boys than in girls before puberty.Therefore,serum levels of AMH in combination with testosterone is used for the differential diagnosis of disorders of sex development,anorchia,non-obstructive azoospermia,and persistent Mullerian duct syndrome.Recently,serum AMH measurements have also been used in fertility preservation programs in oncofertility,screening for granulosa cell tumors,and prediction of menopause applications.In this review,we will focus on clinical application of AMH in fertility assessments for healthy men and women,as well as for cancer patients.展开更多
文摘Infertility is one of the most common non-communicable diseases,affecting both men and women equally.Ovarian reserve,the number of primordial follicles in the ovaries is believed to be the most important determinants for female fertility.Anti-Mullerian hormone(AMH)secreted from granulosa cells of growing follicles is recognized as the most important biomarker for ovarian reserve.Ovarian reserve models have been developed using AMH and other hormonal indicators,thus childbearing plans and reproductive choices could be arranged by women.In assisted reproductive technology cycles,measurement of AMH helps to predict ovarian response and guide recombinant follicle-stimulating hormone dosing in women.Serum AMH level is increasingly being recognized as a potential surrogate marker for polycystic ovarian morphology,one of the criteria for diagnosis of polycystic ovarian syndrome.AMH is also secreted by Sertoli cells of testes in men,and AMH measurements in the prediction of surgical sperm recovery rate in men have also been investigated.AMH levels are significantly higher in boys than in girls before puberty.Therefore,serum levels of AMH in combination with testosterone is used for the differential diagnosis of disorders of sex development,anorchia,non-obstructive azoospermia,and persistent Mullerian duct syndrome.Recently,serum AMH measurements have also been used in fertility preservation programs in oncofertility,screening for granulosa cell tumors,and prediction of menopause applications.In this review,we will focus on clinical application of AMH in fertility assessments for healthy men and women,as well as for cancer patients.
